C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 51.35 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $6.641 million which beat the analyst consensus estimate of $4.000 million by 66.03 percent. This is a 2.75 percent increase over sales of $6.463 million the same period last year.